UPDATE 2-Vir, Alnylam plan human trials by year-end for potential COVID-19 therapy

Vir Biotechnology Inc and Alnylam Pharmaceuticals Inc plan to begin human testing of their COVID-19 drug candidate by the end of the year, as drugmakers across the globe scramble to find therapies for the highly-infectious virus.